HIV / AIDS in the News

Gilead reports positive phase 3 data for HIV treatment combo - Investing.com

 

Key facts: Merck reports $65B sales rise; HIV treatment meets trial goals; health division restructured - TradingView

 

State ducks legal challenge, enacts emergency rule to cut HIV/AIDS medication assistance funding - WLRN

 

Pharmacists may soon prescribe HIV prevention drugs - FOX 5 Atlanta

 

Gilead's experimental HIV treatment shows low discontinuation rates in studies - Reuters

 

Gilead's experimental HIV treatment shows low discontinuation rates in studies - TradingView

 

Novel 1-pill regimen tamps down virus in older adults with HIV, study suggests - CIDRAP

 

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing - GSK

 

Switching to Bictegravir-Lenacapavir Combination Maintains HIV Virologic Suppression in Complex Regimen Patients - Contagion Live

 

what happens if Ryan White ends for HIV AIDS - Infectious Disease Special Edition

 

Once‑every‑4‑months HIV regimen holds virus at bay in ViiV study - Stock Titan

 

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing - Business Wire

 

ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen - Business Wire

 

Pritelivir Demonstrates Superior Efficacy in People Living with HIV with Refractory HSV in Phase 3 PRIOH-1 - Yahoo Finance

 

Gilead paints clearer picture of next-gen HIV tablet's prowess with results from 2 late-stage studies - Fierce Pharma

 

Single daily pill shows promise as replacement for complex, multi-tablet HIV treatment regimens - Medical Xpress

 

New single-pill HIV therapy promises boost for long-term virus survivors - Financial Times

 

A single once-daily pill combining two antiretrovirals simplifies HIV treatment, as demonstrated by a phase 3 trial - Science Media Centre España

 

US funding freeze linked to HIV care disruptions in 32 countries, study finds - Medical Xpress

 

How can PrEP use among Black people be improved? - Advocate.com

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's